Pall collaborates with Aetos for ‘next-gen’ biosimilar manufacturing
Pall has entered an agreement with Aetos Biologics to provide manufacturing solutions for expedited biosimilar development.
Archives for September 26, 2018
Health Canada approves subcutaneous treatment for breast cancer
Halozyme Therapeutics announced that a subcutaneous formulation of trastuzumab created with Halozyme’s technology, for the treatment of breast cancer, has received approval from Health Canada.
Inside the Testa Bioprocess Innovation Center
Biopharma-Reporter takes you inside the recently opened Testa BioProcess Innovation Center in Uppsala, Sweden, and speaks with CEO of GE Nordics, Lotta Ljungqvist.